Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.56 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.56 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.42 |
| ▸ | ARG1 | P05089 | 1/20 | 0.42 |
| ▸ | ARG2 | P78540 | 1/20 | 0.42 |
| ▸ | CES2 | O00748 | 1/20 | 0.41 |
| ▸ | CES1 | P23141 | 1/20 | 0.41 |
| ▸ | CPA1 | P15085 | 3/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | KEAP1 | Q14145 | 1/20 | 0.38 |
| ▸ | FDPS | P14324 | 1/20 | 0.38 |
| ▸ | CRHBP | P24387 | 1/20 | 0.37 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.37 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | NPC1 | O15118 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28243868 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL4362988 | 1.00 | SMN1; SMN2 (0.56) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL7795287 | 0.86 | SMN1; SMN2 (0.49) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 | |
| SCHEMBL3891306 | 0.86 | BLM (0.56) | SMN1; SMN2HIF1ABLMCYP1A2CYP3A4 | |
| SCHEMBL3891311 | 0.86 | BLM (0.56) | SMN1; SMN2HIF1ABLMCYP1A2CYP3A4 | |
| SCHEMBL10717351 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1AARG1ARG2CES2 | |
| SCHEMBL9617912 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2HIF1AARG1ARG2CES2 | |
| SCHEMBL1828129 | 0.77 | SMN1; SMN2 (0.42) | SMN1; SMN2HIF1ASLC6A2TAAR1CES2 | |
| SCHEMBL28360703 | 0.75 | SMN1; SMN2 (0.47) | SMN1; SMN2HIF1AARG1ARG2CES2 | |
| SCHEMBL27548994 | 0.75 | SMN1; SMN2 (0.38) | SMN1; SMN2HIF1ASLC6A2TAAR1ARG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 222 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240008483-A1 | COMPOSITION FOR MOLD REMEDIATION | MOLD GUARD INC. (CA) | 2024-01-11 | — | — | US | claimed |
| CN-116997648-A | Composition for mould repair | 霉菌防护有限公司 | 2023-11-03 | — | — | CN | claimed |
| EP-4244364-A1 | COMPOSITION FOR MOLD REMEDIATION | Mold Guard Inc. (CA) | 2023-09-20 | — | — | EP | claimed |
| WO-2022104023-A1 | COMPOSITION FOR MOLD REMEDIATION | MOLD GUARD INC. (CA) | 2022-05-19 | — | — | WO | claimed |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | TRANSFERT PLUS LP (CA) | 2026-03-26 | — | — | US | disclosed |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | UNIVERSITY OF CONNECTICUT (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250302971-A1 | Therapeutic Nanomaterials | UNIV CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | UNIVERSITY OF CONNECTICUT (US) | 2025-10-02 | — | — | US | disclosed |
| US-20250229081-A1 | NANOMATERIAL COATED ELECTRODE AND METHODS OF USE THEREOF | UNIVERSITY OF CONNECTICUT | 2025-07-17 | — | — | US | disclosed |
| EP-4584301-A1 | CSGA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | Transfert Plus, Limited Partnership (CA) | 2025-07-16 | — | — | EP | disclosed |
| EP-4578867-A1 | CYCLIC PEPTIDE OR SALT THEREOF AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| EP-4578868-A1 | CYCLIC PEPTIDE OR SALT THEREOF, AND MDMX INHIBITOR | FUJIFILM Corporation (JP) | 2025-07-02 | — | — | EP | disclosed |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | HOFFMANN-LA ROCHE, INC. | 2015-02-19 | — | — | US | disclosed |
| US-8927500-B2 | Peptidomimetic macrocycles | AILERON THERAPEUTICS, INC. (US) | 2015-01-06 | — | — | US | disclosed |
| CN-104159595-A | Peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2014-11-19 | — | — | CN | disclosed |
| CN-104144695-A | Triazole-and thioether-crosslinked peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2014-11-12 | — | — | CN | disclosed |
| CN-104039342-A | Peptidomimetic macrocycles | AILERON THERAPEUTICS INC | 2014-09-10 | — | — | CN | disclosed |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. | 2013-10-17 | — | — | US | disclosed |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-08-15 | — | — | US | disclosed |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | AILERON THERAPEUTICS, INC. (US) | 2013-05-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250302971-A1 | Therapeutic Nanomaterials | TIE1, TEKT1, POLRMT | SMN1; SMN2 2104/4885HIF1A 1523/4885SLC6A2 999/4885 |
| US-20250367300-A1 | Nanomaterial and Methods of Use Thereof | EPCAM, CD47, JAK2 | SMN1; SMN2 1218/4885HIF1A 3475/4885SLC6A2 491/4885 |
| US-20250302762-A1 | NANOMATERIAL DELIVERY VEHICLE AND METHOD OF USE THEREOF | JAK2, JAK1, CHMP4B | SMN1; SMN2 84/4885HIF1A 2308/4885SLC6A2 104/4885 |
| US-20150051155-A1 | PEPTIDOMIMETIC MACROCYCLES | TP53, MDM2, MDM4 | SMN1; SMN2 2468/4885HIF1A 2561/4885SLC6A2 4884/4885 |
| US-20260083834-A1 | CsgA-DERIVED NANOSTRUCTURES AND USES THEREOF FOR ANTIGEN DELIVERY | VSIG8, MICA, CD74 | SMN1; SMN2 2636/4885HIF1A 3245/4885SLC6A2 3293/4885 |
| US-20130123169-A1 | PEPTIDOMIMETIC MACROCYCLES | GHRHR, GHSR, GHITM | SMN1; SMN2 2636/4885HIF1A 781/4885SLC6A2 4309/4885 |
| US-20130210745-A1 | TRIAZOLE-CROSSLINKED AND THIOETHER-CROSSLINKED PEPTIDOMIMETIC MACROCYCLES | IL33, TPR, CDC37 | SMN1; SMN2 3907/4885HIF1A 1402/4885SLC6A2 4812/4885 |
| US-20130274205-A1 | PEPTIDOMIMETIC MACROCYCLES | PROKR1, GLP1R, PROKR2 | SMN1; SMN2 1167/4885HIF1A 1052/4885SLC6A2 4788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.